Objective. The aim of this study was to evaluate the impact of introducing tocilizumab (TCZ) as co-therapy with CS in patients with RA.
Introduction
RA is a frequent and disabling disease characterized by synovitis, leading to joint destruction. The physiopathology is complex and involves a variety of immune system mediators. In particular, there is excessive production of IL-6, a cytokine involved in the immune response and the inflammatory reaction. Currently there are no curative treatments. However, the development of biologic therapies has modified the course of the disease and its prognosis. Among these, tocilizumab (TCZ), which inhibits IL-6 activity, has been shown to be more effective than MTX alone, with safety and survival comparable to what is observed with anti-TNF-a therapies [1, 2] .
CS therapy in RA was a therapeutic revolution [3] . However, such therapy, which has both anti-inflammatory and structural effects [4, 5] , has numerous adverse effects, notably infection, osteoporosis and probably cardiovascular diseases, which can occur even in patients treated with low-or moderate-dose regimens [510] . These adverse effects depend on the duration of treatment, dosage and age of the patient. Thus it is currently frequently recommended that oral CSs be used in association with DMARDs, to wait for the effects of DMARDs, and then to reduce the CS dosage as soon as clinically possible [5, 1114] . Moreover, CS sparing appears to be a criterion for changing the DMARD, in particular when the dose of CS therapy is 5 10 mg/day [13, 15] .
However, although it is recommended that the glucocorticoid dosage be kept to a minimum and to attempt to taper glucocorticoids in the case of remission or low disease activity [5] , very little data are available on the feasibility of such tapering. In particular, in patients with prolonged glucocorticoid therapy, reducing the daily dose of steroid might not be that easy, even in the case of remission. There have been very few therapeutic trials using the daily dose of CS as either a primary or secondary outcome criterion. Actually, the dose of CS is rarely mentioned. Indeed, an analysis of the literature that included 66 publications on biotherapy in RA treatment showed that the mean daily dose of CS was only given eight times [16] . One study reported that biotherapy (etanercept, infliximab, adalimumab, anakinra) had a CSsparing effect, with a decrease in the mean daily dose of 3.1 and 4.1 mg at 6 and 12 months, respectively (mean initial dose 8.3 mg) [17] . It has been reported that CS daily dosage can be reduced in 75% of patients during the first year following introduction of anti-TNF-a [1819]. These effects can be observed as early as 3 months after treatment initiation [19] and persist after 5 years [20] . To our knowledge, only one study has assessed CS sparing after initiation of TCZ. This study was a 5-year open extension of a 1-year randomized trial [2] . In patients treated with CSs, the mean daily dose fell from 6.9 mg/day to 2.4 mg/day, and 31.8% of patients were able to stop the therapy. However, patients treated with a daily dose > 10 mg of prednisolone were excluded from the study. Moreover, it did not seek predictive factors for CS sparing. Finally, therapeutic trials are conducted within a restrictive framework and may not reflect exactly what happens in clinical practice. Thus the aim of the present work was to determine the impact of introducing TCZ on daily CS therapy in RA patients in real life and to evaluate potential predictive factors for CS sparing.
Methods

Study design
We conducted a 6-month open, observational, retrospective multicentre study. The study was approved by the local ethics committee (Comité de Protection des Personnes Sud Mé diterrané e IV, Montpellier, France). Statistical analysis was carried out in two parts. The first part was equivalent to an intention-to-treat analysis, in accordance with the last observation carried forward technique. For all of the patients who stopped TCZ before week 24, the data collected at the last visit on TCZ were attributed to the next visit. The same technique was used for missing data. The second part was equivalent to a completer analysis: there were no imputations for missing data and only patients seen at a particular visit were included in the analysis concerning this visit.
Each of the two parts was analysed in the same way. First, a descriptive analysis was performed. Second, the evolution over time of daily doses of oral CS, of the DAS28-ESR and of each of its components and of the CRP was evaluated using analysis of variance (ANOVA) with repeated measures. Third, potential predictive factors for changes in CS daily dose over 24 weeks were evaluated using ANOVA (qualitative variables, MannWhitney or KruskallWallis if non-normal distribution or non-equality of variance) and Pearson's r (quantitative variables). The evaluated potential predictive variables were age, gender, RA duration, erosions on X-rays, positivity for RF and ACPA, number of prior DMARDs, number of prior biotherapies, presence of cotreatment with MTX and dose, baseline daily dose of oral CS, baseline DAS28-ESR and its components and baseline CRP. A multivariate logistic regression analysis was planned if several variables were linked to the 6-month change in CS daily dose with a P < 0.1 in univariate analysis. Finally, a potential correlation between week 024 changes in the daily dose of CS and week 024 changes in the DAS28 (Pearson's r) and response to treatment at week 24 were evaluated. Statistical significance was defined by a P-value < 0.05.
Results
Two hundred and twenty patients [179 women, 41 men, mean age 55. The daily dose of CS was not mentioned in two patients, who were excluded. The study thus concerned the 130 remaining patients. There were 105 women (80.8%) and 25 men, with a mean age of 56.7 years (S.D. 14.0). The mean RA duration was 16.3 years (S.D. 10.4). In most cases RA was active (only five patients in remission and five with low disease activity), with a mean baseline DAS28 score of 5.1 (S.D. 1.4). The mean dose of CS was 10.0 mg/day (S.D. 8.2) prednisone equivalent (91.5, 51.5, 20.0 and 9.2% of patients received a daily dose of 5 5, 10, 15 and 20 mg, respectively). The baseline data are shown in Table 1 .
The mean duration of follow-up was 21.3 weeks (S.D. 5.6). Nineteen patients stopped the treatment after 4 (n = 1), 8 (n = 8) and 12 (n = 10) weeks because of adverse effects (n = 11), primary or secondary failure (n = 6), orthopaedic surgery (n = 1) and pregnancy (n = 1) and 6 were lost to follow-up after 4 (n = 1), 8 (n = 1) and 12 (n = 4) weeks. As the results of the intention-to-treat and completer analyses were similar, we will only present those of the former.
During the study period there was a significant early CS-sparing effect. The mean daily dose of oral CS fell from Table 2 and Fig. 1 ). In parallel, the mean DAS28 during the study period fell from 5.1 (S.D. 1.4) at baseline to 3.0 (S.D. 1.4) at week 24 (P < 0.0001) (Fig. 2) . Details of the evolution of the DAS and its components, the CRP and the response to treatment are shown in Table 2 .
In parallel, among the 90 patients not receiving CS at baseline, 13 received CS during the study period (3, 7, 7 and 6 were receiving CS at week 4, 8, 12 and 24, respectively, with mean daily doses of 10.8 mg (S.D. 8.0), 11.1 mg (S. At the initiation of TCZ, 32.3% of patients (n = 42) were treated with a daily dose of 4 5 mg of prednisone. This proportion increased to 34.6% (n = 45) at week 4, 39.2% (n = 51) at week 8, 44.6% (n = 58) at week 12 and 53.8% (n = 70) at week 24. CS therapy was withdrawn in 1 patient (0.8%) at week 4, 3 patients (2.3%) at week 8, 8 patients (6.2%) at week 12 and 15 patients (11.5%) at week 24.
The week 024 changes in the daily dose of CS were correlated with the baseline daily dose (r = 0.82, P < 0.001). No other predictive factors were found. There was no correlation between the week 024 changes in the daily dose of CS and those in the DAS28 (r = À 0.1, P = 0.2). This absence of correlation remained after adjustment for the baseline dose of CS. There was a trend towards a greater decrease in the daily dose of CS in non-responders than in responders to treatment at week 24: the mean decrease was 6.9 mg/day (S.D. 14.6) in nonresponders, 1.9 mg/day (S.D. 4.4) in moderate responders and 3.2 mg/day (S.D. 4.0) in good responders (P = 0.17, KruskallWallis).
Given these results, two complementary analyses were added a posteriori. In the first one, the baseline daily dose of CSs in week 24 responders and non-responders were compared. Week 24 non-responders had a higher baseline daily dose [14.7 mg (S.D. 14.4) vs 8.9 mg (S.D. 5.5), P = 0.016, MannWhitney). In the second one, patients were separated into two groups: those treated with a baseline CS daily dose equal to the median (10 mg/day) or above and those treated with a baseline daily dose Similar results were obtained on completer analysis (data not shown). For all patients who stopped tocilizumab before week 24 and for all missing data, the data collected at the last visit were attributed to the next visit (last observation carried forward technique). Thus the number of data really collected at each visit are provided in the For all patients who stopped tocilizumab before week 24 and for all missing data, the data collected at the last visit were attributed to the next visit (last observation carried forward technique). The number of data really collected at each visit were 130 (baseline), 125 (week 4), 124 (week 8), 117 (week 12) and 108 (week 24).
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Tocilizumab and CS sparing in RA (r = 0.138, P = 0.28) or the change in the DAS28 (r = 0.174, P = 0.17).
Discussion
This retrospective multicentre study revealed a significant CS-sparing effect within the 24 weeks following the introduction TCZ in daily practice. This effect was early and long-lasting in patients with severe and active RA and was observed when patients not treated with CS at baseline, but who received CS during the follow-up period, were included in a post hoc analysis. This sparing effect seems to be particularly useful since, in a post-marketing study to assess the adverse effects occurring during the first 24 weeks of TCZ in almost 4000 patients, CS therapy of 55 mg/day prednisone equivalent was associated with the onset of severe infection [21] , and since CS are associated with the onset of gastrointestinal perforations in RA. Such perforations have been described in patients on TCZ, although it is not known whether the incidence is increased by this treatment [22] . In the present study, the percentage of patients treated with a dose <5 mg/ day increased from 32.3% to 53.8%, and 11.5% of the patients were able to stop CS after 24 weeks. However, these data are counterbalanced by the fact that some patients not treated with CS at baseline did use CS during the follow-up. The limitations of this study are the open observational design and the absence of a comparator. However, these are the limitations inherent in real-life studies. Another limitation is the retrospective collection of data. However, the patients were followed in reference centres for RA, with standardized case report forms, and the amount of missing data was negligible. Finally, the duration of follow-up was limited and it would be useful to continue to collect data to evaluate whether the results observed are confirmed.
This study strengthens the study by Nishimoto et al. [2] and is complementary to it. Although it provides no longterm data (follow-up of 24 weeks vs 5 years), it shows that the decrease in the dose of CS starts quickly, during the first weeks of treatment, and continues thereafter, and that >10% of patients are able to stop CS after 24 weeks of TCZ. Moreover, it confirms that the effect observed in the strict framework of a therapeutic trial extension is also observed in real life.
A very interesting aspect of this study was the evaluation of predictors of the decrease in the dose of CS. As the mean DAS28 fell substantially and quickly, in parallel with the decrease in CS dose, it could be supposed that there was a relationship between these two variables. It would appear logical for clinicians to decrease the dose of CS in patients who respond best to treatment. Yet, no correlation was found. On the contrary, there was a nonstatistically significant trend towards a greater decrease in the dose of CS in non-responders. The only variable that correlated with the decrease in CS dose was the baseline dose. The explanation seems obvious: the higher the initial dose, the higher the potential decrease of the dose. Nonetheless, this may not be the only reason. Indeed, there was a trend towards a greater reduction in the dose of CS in non-responders. In addition, there was no correlation between the decrease in the DAS28 score and the reduction in the dose of CS, as may have been expected, and there was no relationship between the initial dose and the reduction in dose in patients initially treated with <10 mg/day prednisone equivalent. Finally, the initial dose of CS in non-responders was greater than that in responders. This could be explained by the fact that it is often more difficult to diminish a low dose than a high dose of CS in RA, and that RA in patients with a high initial dose was probably more severe and therefore less likely to respond to treatment. There is, however, an alternative explanation: it is possible that, in patients treated with high doses of CS, in particular >10 mg/day, the clinician's main therapeutic objective is to reduce the dose of CS, even if doing so has a negative impact on disease activity.
This study showed that TCZ led to significant CS sparing during the first months of RA treatment, and that this sparing effect was observed even in non-responders, in whom the treatment could thus have major benefits despite the absence of response. Other studies are now necessary to confirm these findings and to evaluate the hypotheses put forward.
Rheumatology key messages
. Tocilizumab induced a rapid and significant decrease in daily doses of CS in real life. . In RA patients treated with high doses of CS, clinicians' main objective might be to reduce doses. . In non-responders, tocilizumab may have positive effects by allowing a reduction in the dose of CS.
